Joint Pain

 
HealthAshtam

Joint
Pain

JOINT CARE

We have been provided bones as infrastructure. The meeting points of various bones in our body are structured with a synovial fluid for friction free movement and ligaments for stability as also muscles attached to bones thru tendons for range of movements. These are called Joints. In some joints like our backbone there are discs for stability and movements. Wear and tear mechanism wears out these joints giving rise to discomfort and pain especially on movement. Lifestyle plays a big role in keeping joints healthy.

REASONS FOR JOINT PROBLEM

JOINT PAIN MANAGEMENT PROGRAM

  • Products
  • FAQ
  • References
  • What exactly is a joint?

    A joint is where two or more bones are joined together. Joints can be rigid, like the joints between the bones in your skull, or movable, like knees, hips, and shoulders. Many joints have cartilage (KAHRT-lij) on the ends of the bones where they come together. Healthy cartilage helps you move by allowing bones to glide over one another. It also protects bones by preventing them from rubbing against each other.Keeping your joints healthy will allow you to run, walk, jump, play sports, and do the other things you like to do. Physical activity, a balanced diet, avoiding injuries, and getting plenty of sleep will help you stay healthy and keep your joints healthy too.

  • What exactly is "bone and joint health?"

    Musculoskeletal problems include injuries to the bones, joints, muscles, ligaments, or tendons, as well as conditions such as arthritis or osteoporosis. Many people experience these problems when they injure their backs, knees, shoulders, hips or other parts of their bodies.

  • What causes joint inflammation?

    The cause of inflammation is not completely known. Specialists are looking at a combination of factors such as, genetics, injuries that may occur, and one�s lifestyle. It isn�t yet known which one of these factors weighs in most heavily when deciding whether or not a person will develop joint inflammation, but it is known that a combination of the above three risk factors is involved.

  • What is arthritis?

    Arthritis is an inflammation of the joints causing pain and stiffness. It is also one of the most prevalent diseases affecting bones and joints, and the leading cause of disability in those over 15 years old. Those with arthritis may have symptoms prevalent at all times or intermittently. Usually these symptoms get worse in wet or cold weather conditions. The symptoms can also develop after a traumatic event. Currently, there is no cure for arthritis but there are methods to ease the symptoms associated with the disease. Women are more prone to arthritis than men, and it is equally prevalent across races.

  • How is arthritis diagnosed?

    The most common method of diagnosing arthritis is by taking an x-ray of the joint and taking a good patient history. Physicians also use MRI, lab testing, and bone scans to rule other causes of symptoms in or out.

  • What are the symptoms of osteoarthritis?

    There are many symptoms associated with osteoarthritis. However, the most common ones include: pain with weight bearing exercises, pain that increases during the day and decreases with rest, swelling, tenderness, and a grating or catching in the joints.

  • Is a bunion a form of arthritis?

    No, a bunion is not a form of arthritis. It is a type of excess bone growth that is usually located on a person�s foot. Often, it is the body�s response to an increase of force in a specific area, causing excess bone growth.

  • What is tendonitis?

    Despite what many people believe, tendonitis is not a form of arthritis. A word containing the suffix �-itis� is referring to an inflammation of a specific body part. Therefore, tendonitis is the inflammation of a tendon. Being that tendons attach to bones and are located near joints, tendonitis can often mimic arthritis.

  • What is gout?

    Gout is an accumulation of uric acid crystals in the joints caused by an abnormal metabolism of purines. It is accompanied by sudden attacks of extreme pain and tenderness coupled with chills or a low-grade fever. Heat, redness, and swelling are also typically prevalent in the area with gout.

  • What is the treatment for Arthritis ?

    MyHealthWorks recommends following regimen.

    JOINT CARE

    Reversal                                                        Recovery                       Restoration & Maintenance

    GLUCOSAMINE SUPER-X SUNSHINE D3 PROTOMAX
    X-PAIN X-PAIN OIL NANO CURCUMIN
    PRIMROSE OMEGA-369 MULTIMAX
    CALZIM-D SPIRULINA

References

Joint-osteoarthritis Haroyan A1,2, Mukuchyan V3, Mkrtchyan N3, Minasyan N3, Gasparyan S3, SargsyanA3, Narimanyan M4, Hovhannisyan A5. Author information 1 "Erebuni" Medical Center, 14 Titogradian Street, 0087, Yerevan, Armenia. rheumo_arm@yahoo.com. 2 Yerevan State Medical University of Armenia, Koryun 2, 0025, Yerevan, Armenia. rheumo_arm@yahoo.com. 3 "Erebuni" Medical Center, 14 Titogradian Street, 0087, Yerevan, Armenia. 4 Yerevan State Medical University of Armenia, Koryun 2, 0025, Yerevan, Armenia. 5 Anti-doping Service of Republican Centre of Sport Medicine, Acharyan Str., 2/6, Yerevan, Armenia. Abstract BACKGROUND: The aim of this clinical trial was to assess the efficacy and safety of curcuminoid complex extract from turmeric rhizome with turmeric volatile oil (CuraMed) and its combination with boswellic acid extract from Indian frankincense root (Curamin) vs placebo for the treatment of 40- to 70-year-old patients with osteoarthritis (OA). METHODS: The effects of CuraMed 500-mg capsules (333 mg curcuminoids) and Curamin 500-mg capsules (350 mg curcuminoids and 150 mg boswellic acid) taken orally three times a day for 12 weeks in 201 patients was investigated in a three-arm, parallel-group, randomized, double-blinded, placebo-controlled trial. Primary outcome efficacy measures included OA physical function performance-based tests, the WOMAC recommended index of joint pain, morning stiffness, limitations of physical function, and the patients' global assessment of disease severity. RESULTS: Favorable effects of both preparations compared to placebo were observed after only 3 months of continuous treatment. A significant effect of Curamin compared to placebo was observed both in physical performance tests and the WOMAC joint pain index, while superior efficacy of CuraMed vs placebo was observed only in physical performance tests. The effect size compared to placebo was comparable for both treatment groups but was superior in the Curamin group. The treatments were well tolerated. CONCLUSIONS: Twelve-week use of curcumin complex or its combination with boswellic acid reduces pain-related symptoms in patients with OA. Curcumin in combination with boswellic acid is more effective. Combining Curcuma longa and Boswellia serrata extracts in Curamin increases the efficacy of OA treatment presumably due to synergistic effects of curcumin and boswellic acid.

A complex of three natural anti-inflammatory agents provides relief of osteoarthritis pain. Conrozier T, Mathieu P, Bonjean M, Marc JF, Renevier JL, Balblanc JC. Abstract BACKGROUND: Devil's claw (Harpagophytum procumbens), turmeric (Curcuma longa), and bromelain are nutraceuticals that have demonstrated antiinflammatory and analgesic properties and may be potential solutions in the treatment of acute or chronic joint pain. Their analgesic effect, however, is generally considered mild to moderate, and the relevance of their clinical use remains subject to discussion. OBJECTIVES: The aim of the study was to evaluate the clinical relevance of the efficacy of a marketed complex of 3 plant extracts-H procumbens, C longa, and bromelain (AINAT, 650 mg)-in the treatment of degenerative joint pain. METHODS: A multicenter, observational, prospective, open-label survey was conducted in 8 rheumatology centers. The study included 2 groups, 1 group with participants suffering from chronic osteoarthritis (OA) pain and 1 group suffering from acute OA pain. SETTING: The research team carried out the study under daily practice conditions. PARTICIPANTS: A total of 42 patients (36 women; mean age = 67 y) suffering from acute or chronic, degenerative spine or joint pain participated. INTERVENTION: Two 650-mg capsules of AINAT were administered 3 /d to patients with acute pain and 2 �/d to patients with chronic pain. OUTCOME MEASURES: At baseline, and during a follow-up visit at 15 d for the acute pain group and 60 d for the chronic pain group, the research team obtained each participant's global assessment (PGA) and each rheumatologist's global assessment (RGA), as well as each participant's pain score, using for each of them a 100-mm visual analogue scale (VAS). The clinical relevance of the efficacy was evaluated by comparing the outcome measures at endpoint to the values defining the patient acceptable symptom state (PASS) and by comparing the variations (in mm and %) between baseline and endpoint to those defining the minimal clinically important improvement (MCII). Tolerance was also assessed by collecting adverse events at each visit and by using a 4-point scale (very good to bad) at the endpoint. RESULTS: At baseline, the VAS pain score (standard deviation) was 69.1 mm (15.4) and 68.0 mm (18.2) for patients with acute and chronic pain, respectively. At the endpoint, the scores decreased to 42.1 mm (21.1) and 37.8 mm (25.9), respectively. This reduction of pain, as a percentage as well as an absolute value, corresponds to the required definition of MCII, particularly in patients with chronic joint pain. At the endpoint, most of the patients in both groups reached the level of pain defined as the PASS. No withdrawals occurred due to treatment side effects. CONCLUSION: The improvement of joint pain was clinically relevant in patients treated with AINAT for both acute and chronic OA pain. Considering its excellent tolerance profile, the tested complex of 3 plant extracts with antiinflammatory properties may be a valuable and safe alternative to NSAIDs in patients suffering from degenerative joint diseases.

Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Lubis AMT1, Siagian C, Wonggokusuma E, Marsetyo AF, Setyohadi B. Author information 1 Department of Orthopaedic Surgery, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General Hospital, Jakarta, Indonesia. andri_lubis@yahoo.com. Abstract BACKGROUND: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin sulfate. However, there are controversies whether glucosamine-chondroitin sulfate or their combination with methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome of glucosamine-chondroitin sulfate (GC), glucosamine-chondroitin sulfate-methylsulfonylmethane (GCM), and placeboin patients with knee osteoarthritis (OA) Kellgren-Lawrence grade I-II. METHODS: a double blind, randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren-Lawrence grade I-II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, then at 4th, 8th and 12th week after treatment. RESULTS: on statistical analysis it was found that at the 12th week, there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on WOMAC score (p=0.01) and VAS score (p=0.001). Comparing the score difference between weeks, WOMAC score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 (p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and week 12 (p=0.001). CONCLUSION: combination of glucosamine-chondroitinsulfate-methylsulfonylmethane showed clinical benefit for patients with knee OAK ellgrenLawrence grade I-II compared with GC and placebo. GC did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I-II.